Download Library

Download Library

Document Type
Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH abstract - November 2016 (Avet-Loiseau)
Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH abstract - November 2016 (Avet-Loiseau)
Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with MM Who Have Received 1 or More Prior Lines of Therapy - ASH abstract - November 2016 (Xu)
Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with MM Who Have Received 1 or More Prior Lines of Therapy - ASH abstract - November 2016 (Xu)
DRd Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX) - ASH abstract - November 2016 (Chiu)
DRd Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX) - ASH abstract - November 2016 (Chiu)
Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage- Induced ADCP - ASH abstract - November 2016 (Rigalou)
Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage- Induced ADCP - ASH abstract - November 2016 (Rigalou)
DVd Versus Vd Alone for Relapsed or Refractory MM Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor - ASH abstract - November 2016 (Chanan-Khan)
DVd Versus Vd Alone for Relapsed or Refractory MM Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor - ASH abstract - November 2016 (Chanan-Khan)
Frontline Ofatumumab in Combination with Hyper-CVAD for Patients with CD-20 Positive ALL: Interim Result of a Phase II Trial - ASH abstract - November 2016 (Sasaki)
Frontline Ofatumumab in Combination with Hyper-CVAD for Patients with CD-20 Positive ALL: Interim Result of a Phase II Trial - ASH abstract - November 2016 (Sasaki)
Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care in pts with Heavily Pre-Treated & Highly Refractory MM - ASH abstract - November 2016 (Kumar)
Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care in pts with Heavily Pre-Treated & Highly Refractory MM - ASH abstract - November 2016 (Kumar)
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory MM Pts Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action - ASH abstract - November 2016 (Adams)
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory MM Pts Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action - ASH abstract - November 2016 (Adams)
Efficacy of DRd Versus Rd in Relapsed or Refractory MM Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux - ASH abstract - November 2016 (Usmani)
Efficacy of DRd Versus Rd in Relapsed or Refractory MM Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux - ASH abstract - November 2016 (Usmani)
Results of an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH abstract - November 2016 (Chari)
Results of an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH abstract - November 2016 (Chari)
Q3 2016 Results Presentation
Q3 2016 Results Presentation
Bank of America Merrill Lynch Global Healthcare Conference, London, UK - September 2016
Bank of America Merrill Lynch Global Healthcare Conference, London, UK - September 2016
Q3 2016 Results Podcast
Q3 2016 Results Podcast
Interim Report First Half 2016
Interim Report First Half 2016
First Half 2016 Results Presentation
First Half 2016 Results Presentation
First Half 2016 Results Podcast
First Half 2016 Results Podcast
Pharmacodynamic relationship between natural killer cells and daratumumab exposure in multiple myeloma - EHA Poster - June 2016 (Casneuf)
Pharmacodynamic relationship between natural killer cells and daratumumab exposure in multiple myeloma - EHA Poster - June 2016 (Casneuf)
Daratumumab plus bortezomib & dexamethasone Phase 3 CASTOR data - ASCO presentation - June 2016 (Palumbo)
Daratumumab plus bortezomib & dexamethasone Phase 3 CASTOR data - ASCO presentation - June 2016 (Palumbo)
Daratumumab plus Lenalidomide & dexamethasone Phase 3 POLLUX data - EHA presentation - June 2016 (Dimopoulos)
Daratumumab plus Lenalidomide & dexamethasone Phase 3 POLLUX data - EHA presentation - June 2016 (Dimopoulos)
Phase 1b study of subcutaneous daratumumab with recombinant human hyaluronidase in multiple myeloma (PAVO) - ASCO poster - June 2016 (Nahi)
Phase 1b study of subcutaneous daratumumab with recombinant human hyaluronidase in multiple myeloma (PAVO) - ASCO poster - June 2016 (Nahi)
Daratumumab monotherapy compared with real-world control data in heavily pretreated patients with multiple myeloma - EHA E-Poster - June 2016 (Diels)
Daratumumab monotherapy compared with real-world control data in heavily pretreated patients with multiple myeloma - EHA E-Poster - June 2016 (Diels)
Cost per median overall month of survival in multiple myeloma patients with greater than or equal to 3 lines of therapy - ASCO poster - June 2016 (Maiese)
Cost per median overall month of survival in multiple myeloma patients with greater than or equal to 3 lines of therapy - ASCO poster - June 2016 (Maiese)
Goldman Sachs 37th Annual Global Healthcare Conference, Rancho Palos Verdes, CA, US - June 2016
Goldman Sachs 37th Annual Global Healthcare Conference, Rancho Palos Verdes, CA, US - June 2016
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study
Interim Report First Quarter 2016
Interim Report First Quarter 2016
Patterns of idelalisib treatment-emergent lymphocytosis in patients with CLL or SLL - EHA abstract regarding ofatumumab submitted by Gilead - May 2016 (Ghia)
Patterns of idelalisib treatment-emergent lymphocytosis in patients with CLL or SLL - EHA abstract regarding ofatumumab submitted by Gilead - May 2016 (Ghia)